Research ArticleEbola virus

A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity

See allHide authors and affiliations

Science Translational Medicine  03 Jun 2015:
Vol. 7, Issue 290, pp. 290ra89
DOI: 10.1126/scitranslmed.aaa5597

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • Another drug for another virus

    Dr. Johansen and her colleagues are to be congratulated on conducting their study. One can only agree with them that: "Repurposing approved drugs for emerging infections remains a critical resource for potential antiviral therapies". Who can tell what therapeutic benefits of "off-label" testing of FDA-approved therapies may provide?. Not to mention new insights into pathogenic mechanisms of diseases. It is easy to for...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine

Navigate This Article